Discontinued — last reported Q4 '17
DuPont de Nemours, Inc. Indefinite-Lived Research and Development Assets remained flat by 0.0% to $403.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 49.9%, from $804.00M to $403.00M. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -17.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.03B | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $804.00M | $771.00M | $804.00M | $804.00M | $771.00M | $403.00M | $403.00M |
| QoQ Change | — | -21.9% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -4.1% | +4.3% | +0.0% | -4.1% | -47.7% | +0.0% |
| YoY Change | — | — | — | — | -21.9% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -4.1% | +0.0% | +0.0% | -4.1% | -47.7% | -49.9% |